The State Drug Administration approves the listing of 1 class of innovative drug Rosasta capsules (commodity name: Eryjo)

today (December 18), the State Drug Administration issued a notice that it has recently approved the introduction of a class of new(http://Rosasta capsules (commodity name: Arero) to treat anemia caused by chronic kidney disease (CKD) in patients undergoing dialysis treatmentRosasta capsules are not yet available in any other country, making it the first global lying class of 1.1 new drugs in Chinaoraldrug(http://Roxadustat (code-named FG-4592) capsule is the world's first developed small molecule hypoxic-inducing factor protosconocogensylase inhibitor (HIF-PHI) class to treat renal anemiaThe mechanism of the drug's action is to start from the source, through the regulation of the expression of downstream target genes such as erythropoietin and iron metabolism, promote sequestration cell production, improve the absorption and utilization of iron, thereby improving the level of red blood cellsThe physiological action of low-oxygen inducing factor (HIF) not only increases the expression of erythropoietin, but also increases the expression of erythropoietin receptors and proteins that promote iron absorption and circulationrosasta inhibits PH enzymes by simulating ketone-diastolic acid, one of the substrates of protalysine hydroxylase (PH), affecting the role of PH enzymes in maintaining the balance of HIF production and degradation rate, thus achieving the goal of correcting anemiaWhether in patients with chronic kidney disease (CKD) or dialysis, rosastas can effectively improve hemoglobin levels without being affected by the inflammatory state of the patientthethe listing of rosastas capsules could provide new treatments for patients with anemia caused by chronic kidney disease